AndhraNews.net
Home » Features » Health » Breast cancer

Breast cancer


About Breast Cancer

Breast cancer is cancer originating from breast tissue.

The month of October is recognized as National Breast Cancer Awareness Month by the media as well as survivors, family and friends of survivors and/or victims of the disease. A pink ribbon is the universal symbol of breast cancer awareness. It may be worn to honor those who have been diagnosed with breast cancer.

Types

Inflammatory Breast Cancer

Inflammatory Breast Cancer (IBC) is the most aggressive form of breast cancer. Those suffering with this condition will find that their breasts will turn red and inflamed caused by the microscopic tumor cells clogging up lymph vessels.The Inflammatory Breast Cancer is rare and accounts for about 4% of the breast cancer cases. The IBC is the most lethal form of Cancer and accounts 10% of the 39,500 annual deaths from breast cancer.

Research

Signs and Symptoms of Breast cancer

Having malodorous armpits and goopy earwax are considered as signs of breast cancer in womans according to Japanese scientists.

A study showed that a 21-gene test of a patients breast cancer tumour may change doctor and patient treatment decisions, including the need for chemotherapy.

As per a new study scientists found out that Women who are exposed to smoke are at three times higher risk for breast cancer than non-smoking women not exposed to passive smoking.

Mango can protect against colon and breast cancer.

Reasons

Scientists in London have identified a gene that could increase the risk of male breast cancer by 50 per cent. More than 800 male breast cancer patients revealed that mutations in one particular gene - RAD51B that could play a role in the disease.

Breast cancer statistics

Globally, breast cancer is second to lung cancer as the cause of death among women.

The total number of breast cancer patients in Australia was 164,814 in 2008. This figure is estimated to reach 304,511 patients by 2013.

Molecular targeted therapies

The use of molecular targeted therapies as effective forms of cancer therapy is becoming more prevalent. These therapies are specifically designed to target cancer cells, while minimizing the adverse effects on normal cells when compared to cytotoxic chemotherapeutic drugs.

BreastScreen Australia

BreastScreen Australia program provides free mammography services to aid in the early detection of breast cancer and has resulted in oncologists seeing more early stage disease. This, combined with aggressive and targeted therapy has, in turn, resulted in a reduction in the number of locally-advanced and metastatic breast cancer patients in the country.

Reducing breast cancer risk

Eating pomegranates could reduce the risk of breast cancer.

Breast cancer in News

The Trout Group to Host a "Trout Talk" Key Opinion Leader Meeting and Live Webcast on December 18 in New York City
NEW YORK, NY--(Marketwired - December 15, 2015) - The Trout Group, the leading global investor relations and strategic advisory firm servicing the life sciences industry, will host a KOL lunch and live webcast on December 18, at 12 pm ET series. A live webcast of the event will be available at trouttalk.troutgroup.com.

Sunshine Biopharma Acquires All Remaining Worldwide Patents for Its Adva-27a Anticancer Compound
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that it has acquired all of the remaining rights, title and interest in and to all worldwide patents for the Company's Adva-27a anticancer compound

Menssana Research Breath Test Predicts Lung Cancer
NEWARK, NJ--(Marketwired - December 23, 2015) - An advanced new breath test accurately predicted lung cancer in a blinded clinical study.

Lifeline Biotechnologies Summarizes 2015, Looks Forward to 2016
The Company (OTC PINK: LLBO) updates the meaningful activities for the year of 2015 and looks ahead for 2016.

Prima BioMed Initiates Phase IIb Study in Metastatic Breast Cancer
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)

Genetic Technologies Announces Publication of Key Scientific Validation Results in Support of BREVAGenplus(R)
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company") announced today the publication of a new independent study in support of the BREVAGenplus® breast cancer risk assessment test for Caucasian women. The results were published online first in Cancer Epidemiology, Biomarkers & Prevention on December 16, 2015

SuperSonic Imagine Installs Aixplorer(R) Ultrasound System at the Brust-Zentrum Breast Centre in Zurich, Switzerland
SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814), a company specializing in ultrasound medical imaging, today announced the installation of its Aixplorer® Ultrasound System at the Brust-Zentrum Breast Centre in Zürich, Switzerland

Panera Bread Presents $11,128 Check to Cleveland Clinic for Breast Cancer Research on December 14, 2015
CLEVELAND, OH--(Marketwired - December 16, 2015) - Panera Bread was honored to present a check for $11,128.90 to Cleveland Clinic for breast cancer research on December 14th 2015 at 11:30 AM at the University Circle, Ohio Panera Bread

Rodizio Grill(R) Raises More Than $26,000 for the Image Reborn Foundation During Its Nationwide Fundraiser
Rodizio Grill Presents Check to Foundation Founder and Board Members

Aelan Cell Technologies Names Dr. Marek Dobke to Its Scientific Advisory Board
Aelan Cell Technologies announced today the appointment of Dr. Marek Dobke to its Scientific Advisory Board. Dr. Dobke is currently the Head of the Division of Plastic Surgery at the University of California - San Diego (UCSD) School of Medicine and a Professor of Surgery.

Medifocus, Inc. Announces Closing of First Tranche of Units Offering
Medifocus Inc. (TSX VENTURE: MFS) (OTCQX: MDFZF) ("Medifocus" or the "Company") announces that it has completed the first tranche of its previously announced private placement. The Company issued 78.5 Units at a price of U.S. $10,000 per Unit for gross proceeds of U.S. $785,000. Each Unit is comprised of 200,000 common shares of the Company, and 100,000 Series F Common Share purchase warrants

Prima BioMed Progresses Japanese Collaboration
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) today announces important progress in its collaboration with NEC Corporation and Yamaguchi University in Japan. In this collaboration, first announced in May 2015, Prima's IMP321 Antigen Presenting Cell activator (APC) is being combined with a therapeutic vaccine for different carcinoma types that was developed at Yamaguchi University.

Event Cardio Group Crosses Major Hurdle
Event Cardio Group, Inc. (OTCQB: ECGI), a medical device company, is pleased to announce that its Ambulatory Arrhythmia Monitoring System, NowCardio™, has successfully completed its stage 2 audit of compliance to Canadian Medical Devices Conformity Assessment System (CMDCAS)

Phase III data shows Sandoz' proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product
Novartis International AG /Phase III data shows Sandoz' proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Medifocus, Inc. Announces Financial Results for the Six Months Ending September 30, 2015
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company) reported its financial results for the second fiscal quarter ending September 30, 2015.

ITUS Subsidiary Anixa Diagnostics Corporation Appoints Dr. Michael Shepard to Its Scientific Advisory Board
LOS ANGELES, CA--(Marketwired - December 07, 2015) - ITUS Corporation ("ITUS") (NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has added Dr. Michael Shepard to its Scientific Advisory Board. Dr

Advanced Proteome Therapeutics Updates Study of APC 101
VANCOUVER, BC--(Marketwired - December 04, 2015) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) is following up on its news release of April 29, 2015 that reported on testing of APC 101 in the 4T1 mouse model.

Spotlight Innovation Subsidiary CDT Veterinary Therapeutics to Commercialize Crotalin as Cancer Therapeutic for Veterinary Market
Spotlight Innovation Inc. (OTCQB: STLT) announces that it has formed CDT Veterinary Therapeutics, Inc., a subsidiary company to develop cancer therapeutics for the veterinary market. CDT Veterinary Therapeutics is Spotlight Innovation's third subsidiary company, joining Celtic Biotech and Memcine Pharmaceuticals.

Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab
Business Wire IndiaMerck and Pfizer announced the opening of trial sites for an international Phase III study of avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in patients with platinum-resistant/refractory ovarian cancer

Merck and Pfizer Initiate Two Phase III Studies of Investigational Immunotherapy Avelumab in Advanced Gastric and Gastro-esophageal Junction Cancers
Business Wire IndiaMerck and Pfizer announced the initiation of two Phase III studies of avelumab*, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody, in treating advanced or metastatic gastric/gastro-esophageal junction (GEJ) cancers, which are aggressive cancers with poor survival rates

Konica Minolta Area Vice President Named Influential Woman in Business
RAMSEY, NJ--(Marketwired - December 23, 2014) - Dana Drury has been giving back to the community for as long as she can remember.

Prima BioMed Announces Immutep's IMP321 Patent Application Receives Canadian Patent Office Notice of Grant
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company") is pleased to announce that it has received a Notice of Grant from the Canadian Patent Office for Patent application CA 2,732,570 entitled "Use of MHC class II Ligands as Adjuvants for Vaccination and of LAG-3 in Cancer Treatment." This patent is licensed from the Institute Gustave Roussy and Merck Serono SA.

Clinical Validation Study Supporting the Use of BREVAGenplus(R) in Breast Cancer Risk Assessment
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company") announces that findings from a new research study show that adding a panel of 77 single-nucleotide polymorphisms ("SNPs") improves the predictive accuracy of four commonly used breast cancer risk assessment models

The Breast Cancer Research Foundation Announces New Board Members
NEW YORK, NY--(Marketwired - December 16, 2014) - The Breast Cancer Research Foundation (BCRF) announced today the addition of three new members to its Board of Directors. William P. Lauder, Abbe Raven and Maria Baum will join the foundation's esteemed board, which is chaired by Leonard A. Lauder and Kinga Lampert.

ETST, an Emerging Health and Wellness Company, Adds Attorney, Steven Warm, Esq., to the Advisory Board to Assist With Its New Cutting Edge Nutritional Products, Dietary Supplements and All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil Products
BOCA RATON, FL--(Marketwired - December 16, 2014) - Earth Science Tech, Inc. (OTCQB: ETST) ("ETST" or "the Company"), a unique biotechnology company focused on nutraceuticals, bioceuticals and dietary supplements, today announced the addition of Steven Warm, Esq. to its advisory board.

Longer Course of Radiation Treatment for Breast Cancer Patients Means More Need Social Security Disability Insurance
Two-thirds of breast cancer patients who've had surgery endure six to seven weeks of radiation therapy even though studies suggest that a three week course of higher-dose radiation is just as effective, according to a Penn Medicine study published in the Journal of the American Medical Association last week

Medifocus, Inc. Obtains Two Newly Allowed Canadian Patents on the Prevention and Safety for the Treatment for Breast Cancer
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce it has obtained two newly allowed Canadian patents to add to its extensive intellectual properties portfolio of over 100 issued and/or pending USA and Foreign patents covering its two platform technologies for the treatments of Breast Cancer and Prostate Diseases.

Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Immune-Stimulatory Properties of Peregrine Pharmaceuticals' Bavituximab in Models of Breast Cancer
Peregrine Pharmaceuticals, Inc

Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in HER2+ advanced breast cancer at SABCS
Novartis International AG /Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in HER2+ advanced breast cancer at SABCS . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2015 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc

ActiveYards(R) and Certified Dealers' Contribute to Charitable Efforts Close to Community Hearts
ActiveYards® distributes low maintenance fencing solutions with leading designs and exclusive technologies through a highly reputable and experienced dealer network that does great work on the job as well as off the job by volunteering and playing their part in bringing awareness to local and nationwide charities.

Community Benefits From the Year-Round Philanthropy of Hotel in Joliet, Illinois
Any good relationship involves a fair amount of give and take, whether it's between two people or a hotel and its community. And when visitors arrive at the Fairfield Inn & Suites Joliet North/Plainfield, they can feel the effects of that happy balance. Just as the neighborhood embraces the hotel, the hotel has embraced a diverse range of local causes to support over the past year.

Phase III data shows Sandoz' investigational biosimilar filgrastim has similar safety and efficacy as Amgen's NEUPOGEN®
Novartis International AG /Phase III data shows Sandoz' investigational biosimilar filgrastim has similar safety and efficacy as Amgen's NEUPOGEN® . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Medifocus, Inc.'s Technology Featured in a Mediaplanet Sponsored Insert in "USA Today" on Breast Cancer
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announced that its sponsored Mediaplanet insert called "Breast Cancer Care Featuring Giuliana Rancic" has been distributed in today's issue to "USA Today" newspaper subscribers and newsstands throughout the US.

Chicago Surgeons Highlight Sentinel Lymph Node Biopsy for Breast Cancer Patients
An estimated 232,670 women in the United States are expected to be newly diagnosed with invasive breast cancer in 2014. In an effort to help treat newly diagnosed breast cancer patients, the surgeons at Suburban Surgical Care Specialists/Kane Center (SSCS) in Chicago offer a minimally invasive breast surgery procedure known as the sentinel lymph node biopsy.

Jacksonville Plastic Surgeons Discuss Advantages of DIEP Flap Breast Reconstruction
The team of surgeons at Florida Plastic Surgery Group are proud to offer a variety of reconstructive options for women who have overcome breast cancer. Among the many techniques utilized, the surgeons emphasize the potential of the DIEP Flap (deep inferior epigastric artery perforator) surgery

Novartis features innovative immunotherapy, targeted pipeline treatment combinations and long-term data at ASH and SABCS 2014
Novartis International AG /Novartis features innovative immunotherapy, targeted pipeline treatment combinations and long-term data at ASH and SABCS 2014 . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Zumba's Charity Platform Moves the World; Raises Millions for Breast Cancer Research & Lou Gehrig's Disease
MIAMI, FL--(Marketwired - December 01, 2014) - Global fitness leader Zumba announces today that, with the culmination of its latest campaign, close to six million dollars has been raised via its corporate social responsibility initiatives for important causes including finding a cure for Lou Gehrig's disease and funding preventative breast cancer research.

Regen BioPharma Scheduled to Make Presentation at American Society for Hematology's 56th Annual Meeting in San Francisco December 6th - 9th
Regen BioPharma (OTCBB: RGBP) announced today acceptance by the American Society for Hematology of a presentation by Christine Ichim, PhD, senior scientific research consultant to Regen BioPharma, at its annual meeting entitled "NR2F6 (EAR-2) Is a Novel Leukemia Oncogene Whose Cellular Function Is to Regulate Terminal Differentiation of Erythrocytes at the Proerythroblast Stage

Medifocus, Inc. Launches Advertising and Marketing Campaign to Increase Shareholder Awareness of Its Breast Cancer Technology
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today that it has launched an advertising and marketing campaign in the U.S. to increase shareholder awareness geared specifically towards its Adaptive Phased Array (APA) Microwave Focusing Platform, for the treatment of breast cancer

Acellular Dermal Matrix Techniques Successful in Breast Reconstruction Revision Surgery
ARLINGTON HEIGHTS, ILL--(Marketwired - December 30, 2013) - Breast cancer patients undergoing mastectomy increasingly expect excellent cosmetic results after breast reconstruction

Marani Brands CEO Margrit Eyraud Shares Corporate Accomplishments for the Last 90 Days
Marani Brands (OTC Pink: MRIB) CEO Margrit Eyraud shares corporate accomplishments for the last 90 days.

Genetic Technologies Announces Issue of Redeemable Convertible Note and Receipt of Funds
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that the Redeemable Convertible Note (the "Note") described in the Company's ASX announcement dated September 10, 2013, which was subsequently approved by the Company's shareholders at an Extraordinary General Meeting on November 29, 2013, has now been issued.

Genetic Technologies Announces Share Reduction Schedule With Major Shareholder
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that entities associated with the Company's founder and largest shareholder, Dr. Mervyn Jacobson (collectively, the "Jacobson Entities"), have entered into several transactions which will result in the disposal of 105,937,500 shares in the Company. As a result, Dr

Nuvilex's Medical Marijuana Research Could Use Cell Encapsulation Technology to Address Brain Cancers
The executives at Nuvilex, Inc. (OTCQB: NVLX) and its subsidiary, Medical Marijuana Sciences, Inc., had to take note of recent results released in a marijuana study done by a group of researchers in Spain. The study used a type of encapsulation to inhibit brain cancer cell growth in mice

Urban Fashion Icon PINCH NYC Expands 2014 Collection
NEW YORK, NY--(Marketwired - December 18, 2013) - PINCH NYC, a high end urban fashion line, announces additions to its collection for 2014. Launched in 2013, founder Jason Pinchoff was inspired to create a luxury lifestyle brand that combines custom designs with Hip Hop culture for a "Look Good. Do Good" attitude.

MetaStat Announces Poster Presentation at the 2013 San Antonio Breast Cancer Symposium
MetaStat, Inc

Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
Premier Biomedical, Inc

Stellar Biotechnologies Announces Collaboration With Amaran Biotechnology, Inc.
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that it has entered into a collaboration agreement with Amaran Biotechnology, Inc

MetaStat Announces Exclusive Worldwide License Agreements for the Alternative Splicing Program in the Epithelial to Mesenchymal Transition (EMT) in Epithelial Cancers
MetaStat, Inc. (OTCQB: MTST), a life sciences company focused on understanding and treating systemic metastasis, today announced that the company has entered into two separate exclusive worldwide patent and technology license agreements (the "Agreements") with The Massachusetts Institute of Technology ("MIT") and its David H

Medifocus, Inc. Announces, VM Medical Center in Montreal Has Successfully Treated Its First Patient in Its Pivotal Phase III Clinical Trial for Breast Cancer Treatment
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that VM Medical Center in Montreal, its Principal Investigational Site in Canada for its APA-1000 Focused Microwave Breast Thermotherapy System Pivotal Phase III clinical study, has successfully treated its first patient enrolled. Dr. John R

Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2014 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the second quarter of fiscal year (FY) 2014 ended October 31, 2013 and provided an update on its advancing clinical pipeline and other corporate developments.

Living Beyond Breast Cancer Names Vice President
PHILADELPHIA, PA--(Marketwired - December 10, 2013) - Living Beyond Breast Cancer (LBBC) chief executive officer Jean A. Sachs, MSS, MLSP, announced today that Catherine Ormerod has been named Vice President of Programs and Partnerships for this Philadelphia-headquartered nonprofit

My Hope Chest Celebrates 10 Years of Aiding Breast Cancer Survivors
This month, My Hope Chest celebrates its 10 year anniversary as the only national non-profit organization in the nation providing breast reconstruction surgery for under insured and uninsured survivors of breast cancer.

NewLink Genetics Initiates Phase 1 Clinical Trial of NLG919, a Novel Immune Checkpoint Inhibitor for Cancer Immunotherapy
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a first in human Phase 1 clinical trial of NLG919. This is NewLink's second IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor that will initially be tested in patients with recurrent advanced solid tumors

Latteno's Co-Op Valley Organics Introduces New Medical Cannabis Products
Latteno Food Corp.'s (OTC Pink: LATF) wholly-owned subsidiary Co-op Valley Organics, today announced CBD-100, a 100% Organics, 100% Natural Hemp Oil for Medical Cannabis patients. This is an exclusive right to market and distribute with defined term and conditions. Our CBD-100 is made from Canadian Industrial Hemp NOT from Marijuana

Genetic Technologies Announces Publication Highlighting Cost-Effectiveness of BREVAGen(TM) in Cancer Prevention Research
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced its flagship genetic breast cancer risk prediction test, BREVAGen™, is featured in the online issue of Cancer Prevention Research Vol 6 (12): pp 1328 - 36 dated December 5, 2013. The publication profiles the cost-effectiveness of the BREVAGen™ test versus direct MRI screening for breast cancer risk

NANOBIOTIX :strengthens its NanoXray pipeline with the launch of NBTX-TOPO development, the first nanotherapeutic with embedded radar

Confirmatory Testing Affirms Prevention of Metastasis in Premier Biomedical Candidate Therapy for Breast Cancer
Premier Biomedical, Inc

HCG Pinkathon – Almost 3000 Women Run for a Cause in the Fight against Breast Cancer
HCG Pinkathon, International Women’s 10K – Run, was held in Mumbai today, to create awareness on breast cancer and promote health & fitness among women. Almost 3000 women from corporates, colleges, nurses, social clubs and Doctors participated in the run under various categories. The event was organised by HealthCare Global Enterprises Ltd, The Specialist in Cancer Care and was flagged of by Ms

Atossa Genetics Announces Third Quarter 2012 Financial Results
Atossa Genetics, Inc. (NASDAQ: ATOS) today announced financial results for the third quarter of 2012, ended September 30, 2012.

Petra Rietschel MD: Skin Cancer Project Banks on a Cure for Melanoma
The Herald Sun has reported the Melbourne Melanoma Project recently became one of the largest tissue banks in the world. It indicated 1,000 individuals have donated to date. The success the tissue bank has experienced collecting donations caught the attention of physician and medical researcher Petra Rietschel MD who works to help those diagnosed with skin cancer.

Seventh Generation Fields New Corporate Consciousness Report
Seventh Generation, the nation's top brand of non-toxic and renewable bio-based household, baby, and personal care products has released its 2011 Corporate Consciousness Report.

Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2013 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the second quarter ended October 31, 2012 of fiscal year (FY) 2013 and provided an update on its advancing clinical pipeline and other corporate developments.

Sunshine Biopharma Completes Another IND-Enabling Study: Adva-27a Is Found to Be Effective Against Multidrug Resistant Uterine Cancer Cells
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a new IND-Enabling study in which Adva-27a, the Company's flagship oncology drug candidate, was found to be effective at killing Multidrug Resistant Uterine Cancer Cells in vitro

Genetic Technologies Appoints Chief Executive Officer and Non-Executive Director
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) announced today the appointments of Ms. Alison Mew to the position of Chief Executive Officer and Mr. Ben Silluzio as a Non-Executive Director.

Adherex Reports Positive Preliminary Interim Phase II Results for Eniluracil plus 5- Fluorouracil and Leucovorin at the CTRC-AACR San Antonio Breast Cancer Symposium
Patients who had rapid disease progression on capecitabine treatment(1) (N=9) and crossed over to take eniluracil/5-FU/leucovorin (EFL) experienced the following:

The Los Angeles County Affiliate of Susan G. Komen for the Cure(R) Announces Anthem Blue Cross Foundation Grant to Support African American Initiative
The Los Angeles County Affiliate of Susan G. Komen for the Cure® announced today that funding has been provided thanks to a generous grant from the Anthem Blue Cross Foundation

Dubai Lynx Launch Branded Content & Entertainment Category to be Chaired by Mike Weise of TWT
The Dubai Lynx International Festival of Creativity, the leading awards and Festival for creative excellence in communications for the Middle East and Africa region, will launch a new entry section for Branded Content and Entertainment honouring the best work that has delivered marketing messages by engaging consumers via relevant content platforms rather than traditional advertising methods

Sunshine Biopharma Completes Six IND-Enabling Studies for Its Anticancer Compound, Adva-27a
Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed six IND-Enabling studies for Adva-27a, the Company's flagship oncology drug candidate

The International Society for Cancer Risk Assessment and Management (ISC-RAM) Announces First Inaugural Meeting
The International Society for Cancer Risk Assessment and Management (ISC-RAM) is the first international, collaborative, multidisciplinary group whose mission is to advance the field of cancer risk assessment and promote effective strategies for education, surveillance, and cancer risk reduction. The first founders meeting took place on September 23-24th and was sponsored by Atossa Genetics, Inc

Atossa Genetics, Inc. to Present at the 5th Annual LD Micro Conference
Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that Dr. Steven C. Quay, M.D., Ph.D., FCAP, chairman, CEO and president of Atossa Genetics, Inc., will present at the 5th Annual LD Micro Conference on Wednesday, December 5, 2012, at 10:00 AM Pacific Time, at the Luxe Sunset Bel Air Hotel in Los Angeles, California.

Genetic Technologies Provides Update on Board and Management Changes
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) announced today the appointment of Dr. Mal Brandon to the position of Chairman. In addition, Ms. Alison Mew, the Company's Chief Operating Officer will now serve as Acting Chief Executive Officer and Mr. Tom Howitt will continue in his role as Chief Financial Officer. These appointments follow the departure of Directors, Dr. Mel Bridges, Mr

Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
Novartis International AG /Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Advanomics Corporation, the Parent Company of Sunshine Biopharma, Completes Acquisition of Adva-27a Patents
Advanomics Corporation, the parent company of Sunshine Biopharma Inc. (OTCQB: SBFM), is pleased to announce that it has just completed acquisition of the worldwide patents covering Adva-27a from Institut National des Sciences Appliquees, a government research lab in France

eBags.com Surpasses 2.5 Million Customer Reviews
Online retailer eBags.com announced they surpassed 2.5 million customer reviews on their website. Ranked #103 on the Internet Retailer Top 500, eBags.com is the leading ecommerce site for luggage, handbags, laptop bags, backpacks, and accessories.

Get Movin' for a Cause With the Inspiring Zumba(R) Instructors Featured as In-Game Avatars in Zumba(R) Fitness Core
Majesco Entertainment Company (NASDAQ: COOL), an innovative provider of video games for the mass market and makers of the best-selling Zumba® Fitness video game franchise, is showcasing five extraordinary Zumba® instructors who appear as in-game avatars within the new Zumba® Fitness Core video game

Cambridge Heart Reports Results for the Three and Nine Months Ended September 30, 2012
Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today reported results for the three and nine months ended September 30, 2012. Full financial statements and corresponding commentary can be found in the Company's Form 10-Q, which will be filed with the Securities and Exchange Commission on November 14, 2012.

Keiretsu Forum Angel Investors Spread Their Wings
Over 300 of the Bay Area's most active and respected angel investors attended the Keiretsu Forum Angel Capital Expo at the Julia Morgan Ballroom in San Francisco on November 15th. The all-day event featured 12 company presentations and 5 updates, discussion at the presenters' exhibition booths, and the "Most Valued Company" competition, which capped off the day

Corporate Social Responsibility Weekly Recap (November 28, 2012 – December 5, 2012)
The following releases focus on Corporate Social Responsibility and moved during the week of November 28, 2012 – December 5, 2012.

Meditation improves breast cancer survivors' emotional and physical well-being
Mindfulness-based meditation plays a vital role in improving breast cancer survivors' health challenges, which they face after treatments, a new study has revealed.

Brit women told to remove boob implants amid cancer fears
As French authorities issue cancer alert, thousands of British women have been told to get their breast implants removed in case they are worried.

One Tree Hill's Sophia Bush Spearheads Mozilla Firefox Charity Contest for FCancer
Editors note: There are photos accompanying this release.

New Year's Resolutions: eHealthInsurance Shows That Keeping Health-Related Goals May Save You Money
Today eHealthInsurance (NASDAQ: EHTH), the leading online source of health insurance for individuals, families and small businesses, described how keeping your New Year's resolutions and utilizing key health insurance benefits can help you save money.

Year in Review: Healthline Networks Unveils Top 10 Health Searches on Web and Mobile
Healthline Networks, the leading health search and information services provider, today released the most searched health terms across the Healthline HealthWeb in 2011, revealing that people using desktops and laptops search for more serious conditions, such as diabetes and cancer

Genetic Technologies Appoints Dr. Mel Bridges as Chairman
The Board of Directors of Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) has with great pleasure appointed Dr. Mel Bridges as Chairman and non-executive Director of the Company.

Hormone replacement therapy ups breast cancer risk
Researchers have found convincing evidence that use of hormone replacement therapy (HRT) increases risk of breast cancer.

Soon, light to measure cancer cells' response to treatment
Scientists have developed new ways to rapidly measure cancer cells' response to drugs and treatment using light, which could help in improving patient outcomes.

Gene behind breast cancer may also cause heart disease
An Indian origin surgeon has suggested that women who are at risk for breast cancer may also be at greater risk for heart disease.

WIN Consortium Announces the Scientific Program of WIN 2012 Symposium Where Leaders from Academia, Industry and Regulatory Agencies Will Debate Ways to Improve Efficacy of Cancer Therapeutics in Individual Patients
The 4th WIN Symposium in Personalized Cancer Medicine, to be held in Paris, France, June 28-29, 2012 (WIN 2012), will be again this year the unique forum featuring high-ranking speakers from academia, industry and regulatory agencies worldwide

Comment on this story

Share